Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP8 | P22894 | 2/20 | 0.44 |
| ▸ | CYP4F2 | P78329 | 3/20 | 0.39 |
| ▸ | CYP4A11 | Q02928 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.37 |
| ▸ | PKM | P14618 | 3/20 | 0.37 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7512223 | 0.89 | MMP8 (0.52) | MMP8CYP4F2CYP4A11ALDH1A1PKM | |
| SCHEMBL3343065 | 0.80 | MMP8 (0.48) | MMP8CYP4F2CYP4A11ALDH1A1PKM | |
| SCHEMBL2316349 | 0.78 | MMP8 (0.47) | MMP8CYP4F2CYP4A11ALDH1A1PKM | |
| SCHEMBL3166224 | 0.78 | MMP8 (0.47) | MMP8CYP4F2CYP4A11ALDH1A1PKM | |
| SCHEMBL17617135 | 0.78 | ALDH1A1 (0.44) | MMP8CYP4F2CYP4A11ALDH1A1PKM | |
| SCHEMBL13917988 | 0.78 | ALDH1A1 (0.45) | MMP8CYP4F2CYP4A11ALDH1A1PKM | |
| SCHEMBL17617190 | 0.78 | ALDH1A1 (0.44) | MMP8CYP4F2CYP4A11ALDH1A1PKM | |
| SCHEMBL9727892 | 0.75 | MMP8 (0.44) | MMP8CYP4F2CYP4A11ALDH1A1PKM | |
| SCHEMBL15109683 | 0.75 | MMP8 (0.44) | MMP8CYP4F2CYP4A11ALDH1A1PKM | |
| SCHEMBL8867361 | 0.75 | MEN1 (0.40) | MMP8CYP4F2CYP4A11ALDH1A1PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3347361-B1 | TRICYCLIC PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | HOFFMANN LA ROCHE (CH) | 2020-08-05 | — | — | EP | disclosed |
| US-10435414-B2 | Tricyclic PI3K inhibitor compounds and methods of use | GENENTECH, INC. (US) | 2019-10-08 | — | — | US | disclosed |
| US-20180327420-A1 | TRICYCLIC PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2018-11-15 | — | — | US | disclosed |
| US-10065970-B2 | Tricyclic PI3K inhibitor compounds and methods of use | GENENTECH, INC. (US) | 2018-09-04 | — | — | US | disclosed |
| EP-3347361-A1 | TRICYCLIC PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | H. Hoffnabb-La Roche Ag (CH) | 2018-07-18 | — | — | EP | disclosed |
| US-20180162873-A9 | TRICYCLIC PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2018-06-14 | — | — | US | disclosed |
| US-20180065983-A1 | TRICYCLIC PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2018-03-08 | — | — | US | disclosed |
| WO-2017042182-A1 | TRICYCLIC PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | F. HOFFMANN-LA ROCHE AG (CH) | 2017-03-16 | — | — | WO | disclosed |
| EP-1202974-A1 | PYRIMIDINE-2,4,6-TRIONE METALLOPROTEINASE INHIBITORS | Pfizer Products Inc. (US) | 2002-05-08 | — | — | EP | disclosed |
| WO-2001012611-A1 | PYRIMIDINE-2,4,6-TRIONE METALLOPROTEINASE INHIBITORS | PFIZER PRODUCTS INC. (US) | 2001-02-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10435414-B2 | Tricyclic PI3K inhibitor compounds and methods of use | PIK3CA, PIK3CD, PIK3CB | MMP8 1980/4885CYP4F2 2414/4885CYP4A11 716/4885 |
| US-20180065983-A1 | TRICYCLIC PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | PIK3CA, PIK3CD, PIK3CB | MMP8 1980/4885CYP4F2 2414/4885CYP4A11 716/4885 |
| US-20180162873-A9 | TRICYCLIC PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | PIK3CA, PIK3CD, PIK3CB | MMP8 1980/4885CYP4F2 2414/4885CYP4A11 716/4885 |
| US-20180327420-A1 | TRICYCLIC PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | PIK3CA, PIK3CD, PIK3CB | MMP8 1980/4885CYP4F2 2414/4885CYP4A11 716/4885 |
| US-10065970-B2 | Tricyclic PI3K inhibitor compounds and methods of use | PIK3CA, PIK3CD, PIK3CB | MMP8 1980/4885CYP4F2 2414/4885CYP4A11 716/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.